CD274 and head and neck squamous cell carcinoma: PD-L1 was further evaluated as a biomarker in the KESTREL study (NCT02551159) of durvalumab with or without tremelimumab versus the EXTREME regimen in patients with R/M HNSCC who had not received prior systemic therapy [11].